Notas do episódio
This week, we dissect the immediate fallout from Brazil's surprise new regulation, ANVISA RDC 925/2026. This sudden rule change for AI-powered medical software has blindsided many international MedTech companies, creating significant new hurdles for entry into Latin America's largest market.
We explore how the mandate for local Brazilian clinical data and stringent LGPD-aligned cybersecurity protocols is forcing companies to scrap their existing market access strategies. This isn't just another piece of red tape. it's a fundamental shift that could delay product launches by more than a year…
Site: pureglobal.com

